In lung adenocarcinoma, epidermal growth factor receptor (EGFR) mutations were frequently found with concomitant genetic alterations of which the impact on resected EGFR‐mutant lung adenocarcinoma was infrequently reported.We retrospectively reviewed 637 patients and found that TP53 mutation and EGFR amplification were poor prognostic factors for recurrence‐free survival. This evidence concerns the gene TP53 and lung adenocarcinoma.